TRVI
Trevi Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.45 / 10
Netural
Analyst consensus is overwhelmingly bullish (83% Strong Buy, 17% Buy), yet historical win rates are mixed, with only one analyst showing 66% success. Fund‑flow score is 7.79/10, indicating strong inflows across all investor sizes. Sentiment remains neutral.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
83%
Buy
17%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-09
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate0.0%
Is money flowing into or out of TRVI?
- TRVI holds a Bearish analyst rating, with 83% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.45/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
